| Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection M Julsgaard, LA Christensen, PR Gibson, RB Gearry, J Fallingborg, ... Gastroenterology 151 (1), 110-119, 2016 | 352 | 2016 |
| Azathioprine treatment during lactation LA Christensen, JF Dahlerup, MJ Nielsen, JF Fallingborg, K Schmiegelow Alimentary pharmacology & therapeutics 28 (10), 1209-1213, 2008 | 227 | 2008 |
| Long-term safety ofin uteroexposure to anti-TNFα drugs for the treatment of inflammatory bowel disease: Results from the multicenter European TEDDY study M Chaparro, A Verreth, T Lobaton, E Gravito-Soares, M Julsgaard, ... Official journal of the American College of Gastroenterology| ACG 113 (3 …, 2018 | 181 | 2018 |
| European Crohn’s and colitis guidelines on sexuality, fertility, pregnancy, and lactation J Torres, M Chaparro, M Julsgaard, K Katsanos, Z Zelinkova, M Agrawal, ... Journal of Crohn's and Colitis 17 (1), 1-27, 2023 | 120 | 2023 |
| Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti‐TNF or conventional therapy: results of the European CONCEIVE study A Moens, CJ van der Woude, M Julsgaard, E Humblet, J Sheridan, ... Alimentary pharmacology & therapeutics 51 (1), 129-138, 2020 | 114 | 2020 |
| Self-reported adherence to medical treatment prior to and during pregnancy among women with ulcerative colitis M Julsgaard, M Nørgaard, CL Hvas, D Buck, LA Christensen Inflammatory bowel diseases 17 (7), 1573-1580, 2011 | 105 | 2011 |
| Self‐reported antenatal adherence to medical treatment among pregnant women with Crohn’s disease MJ Nielsen, M Nørgaard, P Holland‐Fisher, LA Christensen Alimentary pharmacology & therapeutics 32 (1), 49-58, 2010 | 77 | 2010 |
| Fecal calprotectin is not affected by pregnancy: clinical implications for the management of pregnant patients with inflammatory bowel disease M Julsgaard, CL Hvas, RB Gearry, T Vestergaard, J Fallingborg, ... Inflammatory bowel diseases 23 (7), 1240-1246, 2017 | 72 | 2017 |
| Polymorphisms in the NF kB, TNF‐alpha, IL‐1beta, and IL‐18 pathways are associated with response to anti‐TNF therapy in Danish patients with inflammatory bowel disease S Bank, M Julsgaard, OK Abed, J Burisch, J Broder Brodersen, ... Alimentary pharmacology & therapeutics 49 (7), 890-903, 2019 | 70 | 2019 |
| Self-reported adherence to medical treatment, breastfeeding behaviour, and disease activity during the postpartum period in women with Crohn’s disease M Julsgaard, M Nørgaard, CL Hvas, A Grosen, S Hasseriis, ... Scandinavian Journal of Gastroenterology 49 (8), 958-966, 2014 | 48 | 2014 |
| Adherence and quality of care in IBD P Bager, M Julsgaard, T Vestergaard, LA Christensen, JF Dahlerup Scandinavian Journal of Gastroenterology 51 (11), 1326-1331, 2016 | 36 | 2016 |
| Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease A Grosen, M Julsgaard, J Kelsen, LA Christensen Journal of Crohn's and Colitis 8 (2), 175-176, 2014 | 35 | 2014 |
| Anti-TNF therapy in pregnant women with inflammatory bowel disease: effects of therapeutic strategies on disease behavior and birth outcomes M Julsgaard, CL Hvas, RB Gearry, PR Gibson, J Fallingborg, MP Sparrow, ... Inflammatory bowel diseases 26 (1), 93-102, 2020 | 31 | 2020 |
| Development of a sexual dysfunction scale for women with inflammatory bowel disease PS de Silva, A O’Toole, LG Marc, CA Ulysse, MA Testa, M Julsgaard, ... Inflammatory bowel diseases 24 (11), 2350-2359, 2018 | 31 | 2018 |
| Vedolizumab concentrations in the breast milk of nursing mothers with inflammatory bowel disease M Julsgaard, J Kjeldsen, BM Bibby, B Brock, DC Baumgart Gastroenterology 154 (3), 752-754. e1, 2018 | 31 | 2018 |
| vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease. M Julsgaard, J Kjeldsen, B Brock, DC Baumgart Alimentary Pharmacology & Therapeutics 48 (3), 386-388, 2018 | 26 | 2018 |
| Vedolizumab safety in pregnancy and newborn outcomes M Julsgaard, J Kjeldsen, DC Baumgart Gut 66 (10), 1866-1867, 2017 | 25 | 2017 |
| Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population‐based cohort study M Julsgaard, DC Baumgart, SMD Baunwall, MM Hansen, A Grosen, ... Alimentary Pharmacology & Therapeutics 54 (10), 1320-1329, 2021 | 24 | 2021 |
| Semen quality and sperm DNA integrity in patients with severe active inflammatory bowel disease and effects of tumour necrosis factor-alpha inhibitors A Grosen, M Bungum, LA Christensen, E Cordelli, OH Larsen, G Leter, ... Journal of Crohn's and Colitis 13 (5), 564-571, 2019 | 21 | 2019 |
| I-CARE, a European prospective cohort study assessing safety and effectiveness of biologics in inflammatory bowel disease L Peyrin-Biroulet, JF Rahier, J Kirchgesner, V Abitbol, S Shaji, A Armuzzi, ... Clinical Gastroenterology and Hepatology 21 (3), 771-788. e10, 2023 | 20 | 2023 |
Christian Lodberg HvasAssociate professor在 rm.dk 的电子邮件经过验证
